CytRx Corp (NASDAQ:CYTR)
| CAPS Rating |
|
|---|---|
| Open | $0.37 |
| Previous Close | $0.35 |
| Daily Range | $0.35 - $0.38 |
| 52-Week Range | $0.24 - $1.06 |
| Market Cap | $56.05M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,264,876 |
| Average Daily Volume | 0 |
CYTR
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CYTR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CYTR News and Commentary
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog – NASDAQ
- Hot summer bottoms – Blog at The Motley Fool
- Stocks Mixed at Session's Half; Gold Tops $1,500 an Ounce, Oil Gains – NASDAQ
- Mid-Day Update: Stocks Flat While Commodities Jump Following Long Holiday Weekend – NASDAQ
- CytRx's INNO-206 Gets Orphan Drug Status For Soft Tissue Sarcoma – SmartMoney
- CytRx: A Cancer Drug Developer Evidently Undervalued – SeekingAlpha
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance – NASDAQ
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise – NASDAQ
- 13 Small - Micro Cap Stocks Turning Profitable – SeekingAlpha
- Drug Pipeline Pulse Check: Spectrum, QRxPharma, CytRx and Impax – SeekingAlpha
- China Analyst: 10 Pharma Stocks With Highest Growth Potential – SeekingAlpha
- Are RNAi Leaders About to Be Snatched Up by Big Pharma? – SeekingAlpha
- Query - CYTR spin-off in March 2008 .... – Blog at The Motley Fool
- UPDATE 1-CytRx says prelim results of cancer drug shows promise – Reuters
- Behind the Business: 3 Questions for Vical – The Motley Fool
- UPDATE 1-CytRx says FDA lifts clinical hold on Lou Gehrig's drug – Reuters
Related News and Articles
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
RSS Headlines
Fool UK
